CHERIKA O'BRIEN: Open Payments
NPI 1174284558 · RICHMOND, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,075 in 69 payments from 17 companies in 2025. Trend: 2023 $0 · 2024 $787 · 2025 $1,075
Food & beverage: $1,075
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $318 |
| Vanda Pharmaceuticals Inc. | 10 | $165 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $149 |
| PFIZER INC. | 4 | $75 |
| Gilead Sciences, Inc. | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Lundbeck LLC | 2 | $36 |
| Corium, LLC | 2 | $34 |
| GlaxoSmithKline, LLC. | 2 | $31 |
| Indivior Inc. | 2 | $30 |
Products named: VRAYLAR, FANAPT, CAPLYTA, QULIPTA, NURTEC ODT, REXULTI, UBRELVY, Azstarys.
Industry payments across IN — which companies pay providers there.
